Qiagen Weighs Stake Sale In $1 Billion Bioinformatics Arm- Bloomberg News

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM RAPIDE-1 STUDY OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS * PHARVARIS NV - PRIMARY ENDPOINT MET,

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * PHARVARIS NV - EXECUTING FROM A STRONG FINANCIAL POSITION WITH CASH AND CASH

8 December 2022 12:35 p.m. ​All figures in euros. The loss announced by Pharvaris NV in the third quarter were higher than the Refinitiv mean estimate of losses. The company reported losses of -25

* Pharvaris NV reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended in September. The mean expectation of five analysts for the quarter was for a loss of 63 cents per share

23 November 2022 11:02 a.m. All figures in euros. Pharvaris NV is expected to show a decrease in its third quarter earnings to -63 cents​ per share according to the mean Refinitiv estimate from five

* Pharvaris NV is expected to show no change in quarterly revenue when it reports results on November 25 (estimated). * * ​Refinitiv's mean analyst estimate for Pharvaris NV is for a loss of 63 cents

11 November 2022 05:04 p.m. All figures in euros. LAVA Therapeutics NV is expected to show an increase in its third quarter earnings to -14 cents​ per share according to the mean Refinitiv estimate

* ProQR Therapeutics NV reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended in September. The mean expectation of seven analysts for the quarter was for a loss of 21 cents

9 November 2022 01:50 p.m. ​All figures in euros. The loss announced by ProQR Therapeutics NV in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of

Nov 9 (Reuters) - Proqr Therapeutics Nv: * PROQR ANNOUNCES THIRD QUARTER 2022 OPERATING AND FINANCIAL RESULTS * QTRLY LOSS PER SHARE EUR 0.34 * REPAYMENT OF DEBT WITH CASH RUNWAY INTO 2026 * Q3